Supercharge Your Innovation With Domain-Expert AI Agents!

Pharmaceutical combinations for the treatment of metabolic disorders

a metabolic disorder and combination therapy technology, applied in the field of pharmaceutical combinations, can solve the problems of affecting the treatment effect of athersclerosis, so as to prevent the progression of delaying or treating athersclerosis and slow the progression

Inactive Publication Date: 2013-08-29
BOEHRINGER INGELHEIM INT GMBH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about a new invention of pharmaceutical compositions and methods that can be used to treat various diseases and conditions. The invention involves combining two different active ingredients, which can have better effects than using just one ingredient alone. This can include increased efficacy, stronger dosage, more frequent dosing, and reduced adverse effects. The combination can also work more effectively in controlling blood sugar levels in hyperinsulinemic or diabetic non-human primates. The invention can reduce the amount of active ingredients needed and improve glycemic control compared to monotherapy. The patent also mentions that pharmaceutically acceptable carriers are already known in the art.

Problems solved by technology

In addition, the presence of type 2 diabetes is associated with a two to five fold increase in cardiovascular disease risk.
In addition, even in patients within the intensive treatment arm glycemic control deteriorated significantly over time and this was attributed to deterioration of β-cell function.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical combinations for the treatment of metabolic disorders
  • Pharmaceutical combinations for the treatment of metabolic disorders
  • Pharmaceutical combinations for the treatment of metabolic disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Dry Ampoule Containing 75 Mg of Active Substance Per 10 ml

Composition:

[0241]

Active substance75.0mgMannitol50.0mgwater for injectionsad 10.0mlPreparation:Active substance and mannitol are dissolved in water. After packaging the solution is freeze-dried. To produce the solution ready for use, the product is dissolved in water for injections.

example 2

Dry Ampoule Containing 35 mg of Active Substance Per 2 ml

Composition:

[0242]

Active substance35.0mgMannitol100.0mgwater for injectionsad 2.0mlPreparation:Active substance and mannitol are dissolved in water. After packaging, the solution is freeze-dried.

[0243]To produce the solution ready for use, the product is dissolved in water for injections.

example 3

Tablet Containing 50 mg of Active Substance

Composition:

[0244]

(1) Active substance50.0 mg(2) Lactose98.0 mg(3) Maize starch50.0 mg(4) Polyvinylpyrrolidone15.0 mg(5) Magnesium stearate 2.0 mg215.0 mg Preparation:(1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.Diameter of the tablets: 9 mm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
diastolic blood pressureaaaaaaaaaa
Login to View More

Abstract

The invention relates to a pharmaceutical composition comprising 1.a and / or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Description

TECHNICAL FIELD OF THE INVENTION[0001]The invention is directed to pharmaceutical combinations comprising an inhibitor of 11-beta-hydroxysteroid dehydrogenase 1 of formula 1.a or 1.b as one active ingredient in combination with at least one additional active ingredient 2 which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, dyslipidemia / hyperlipidemia.[0002]Furthermore the invention relates to methods[0003]for preventing, slowing progression of, delaying, or treating a metabolic disorder;[0004]for improving glycemic control and / or for reducing of fasting plasma glucose, of postprandial plasma glucose and / or of glycosylated hemoglobin HbA1c;[0005]for preventing, slowing, delaying or reversing progression from impaired glucose tolerance, impaired fasting blood glucose, insulin resistance and / or from metabolic syndrome to type...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5355A61K45/06
CPCA61K31/155A61K31/422A61K31/427A61K31/522A61K31/5355A61K45/06A61K31/7048A61K2300/00A61P13/12A61P25/00A61P27/02A61P27/06A61P3/00A61P3/04A61P3/06A61P3/08A61P43/00A61P7/00A61P9/00A61P9/10A61P3/10A61K31/535A61K31/4412
Inventor HAMILTON, BRADFORD S.RAUCH, THOMASTSUTSUMI, MANAMI
Owner BOEHRINGER INGELHEIM INT GMBH
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com